Wayne State University, Barbara Ann Karmanos Cancer Institute, Department of Oncology, Department of Medicine, 4 Hudson Webber Cancer Research Center, 4100 John R, Detroit, MI 48201, USA.
Expert Opin Biol Ther. 2013 Feb;13(2):269-82. doi: 10.1517/14712598.2012.758705. Epub 2013 Jan 4.
Over the last decade, the field of oncology has undergone revolutionary changes. One of the major reasons contributing to this change is the improvement in our understanding of the biology of cancer. Recognition of novel targets on the cancer cell has enabled development of tools to attack those targets. Monoclonal antibodies represent such a therapy that has rapidly been adapted in almost all major cancer subtypes.
This review intends to give a comprehensive overview of monoclonal antibodies, including mechanism of action, the currently approved agents and future targets. The authors reviewed published data as well as information from the ongoing clinical trials.
Monoclonal antibodies represent a major new advance in oncology therapy but there remains significant room for improvement.
在过去的十年中，肿瘤学领域发生了革命性的变化。促成这一变化的主要原因之一是我们对癌症生物学的理解得到了提高。对癌细胞上的新靶点的认识使开发攻击这些靶点的工具成为可能。单克隆抗体就是这样一种治疗方法，它已经迅速应用于几乎所有主要的癌症亚型。
本文旨在全面概述单克隆抗体，包括作用机制、目前批准的药物和未来的靶点。作者综述了已发表的数据以及正在进行的临床试验的信息。
单克隆抗体代表了肿瘤学治疗的重大新进展，但仍有很大的改进空间。
